Therapy Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Therapy Name	Cyclophosphamide + Cytarabine + Daunorubicin + Etoposide + Fludarabine + Imatinib + Melphalan + Mercaptopurine + Methotrexate + Pegaspargase + Rituximab + Vincristine Sulfate
Synonyms
Therapy Description

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Filter rows:

Showing 1 to 12 of 12 entries

Drug Name	Trade Name	Synonyms	Drug Classes	Drug Description
Cyclophosphamide	Cytoxan	CPM	Chemotherapy - Alkylating 18	Cytoxan (cyclophosphamide) is an alkylating agent, which inhibits DNA replication (NCI Drug Dictionary). Cytoxan (cyclophosphamide) is FDA approved in multiple hematological malignancies, breast cancer, neuroblastoma, ovarian cancer, and retinoblastoma (NCI Drug Dictionary).
Cytarabine	Cytosar-U	Ara-C		Cytosar-U (cytarabine) is a cytidine analog that, when incorporated into DNA, inhibits DNA synthesis and repair (PMID: 32524309).
Daunorubicin	Cerubidine	Rubidomycin\|daunomycin hydrochloride\|rubomycin C\|Acetyladriamycin	Chemotherapy - Anthracycline 13	Cerubidine (daunorubicin) is an anthracycline, which inhibits DNA replication and repair. Cerubidine (daunorubicin) is FDA approved for AML and MLL (FDA.gov).
Etoposide	Vepesid	EPEG\|Eposin\|VP-16\|VP-16-213	TOPO2 inhibitor 5	Vepesid (etoposide) binds to and inhibits DNA topoisomerase II, resulting in accumulated DNA damage, inhibition of replication, and cell death (NCI Drug Dictionary).
Fludarabine	Fludara	FAMP\|Fludarabine phosphate		Flurdara (fludarabine) is converted to 2-fluoro-ara-ATP intracellularly, which potentially inhibits DNA polymerase alpha, ribonucleotide reductase and DNA primase, leading to decreased DNA synthesis and reduced tumor growth (NCI Drug Dictionary)
Imatinib	Gleevec	CGP-57148B\|STI571\|Imatinib mesylate	ABL Inhibitor (pan) 9 BCR-ABL Inhibitor 32 CSF1R Inhibitor 28 KIT Inhibitor 57 PDGFR Inhibitor (Pan) 30	Gleevec (imatinib) is a multi-target inhibitor of c-Kit, Pdgfr, and Bcr-Abl (PMID: 12200353). Gleevec (imatinib) is FDA approved for c-KIT positive GIST and dermatofibrosarcoma protuberans, Philadelphia chromosome positive chronic myeloid leukemia, and FIP1L1-PDGFRA positive chronic eosinophilic leukemia (FDA.gov).
Melphalan	Alkeran		Chemotherapy - Alkylating 18	Alkeran (melphalan) is an antineoplastic alkylating agent, which cross-links DNA and induces cell toxicity and is FDA approved for multiple myeloma and epithelial ovarian carcinoma (FDA.gov).
Mercaptopurine	Purixan	6 MP\|Purinethol
Methotrexate	Abitrexate	Amethopterin	Chemotherapy - Antimetabolite 14	Methotrexate is an antimetabolite, which inhibits DHFR resulting in decreased immune function and antineoplastic activity and is FDA approved for psoriasis, RA, and several cancers including choriocarcinoma, AML, lung, head and neck and epidermoid (FDA.gov).
Pegaspargase	Oncaspar	PEG-asparaginase\|PEG-ASP		Oncaspar (pegaspargase) is a pegylated version of L-asparaginase, which converts L-asparagine to ammonia and L-aspartic acid, reducing available asparagine resulting in decreased protein synthesis, inhibition of tumor cell proliferation, and increased apoptosis (NCI Drug Dictionary).
Rituximab	Rituxan	IDEC-C2B8\|MabThera	CD20 Antibody 25	Rituxan (rituximab) is a chimeric mononclonal antibody that binds to CD20 on B-cells, resulting in induction of complement-dependent and antibody-dependent cytotoxicity, and potentially leading to decreased B-cell tumor growth (PMID: 28983798). Rituxan (rituximab) is FDA approved for use as monotherapy or in combination with chemotherapy in CD20-positive B-cell non-Hodgkin lymphoma, in combination with fludarabine and cyclophosphamide in CD20-positive chronic lymphocytic leukemia, and in combination with chemotherapy in pediatric patients (6 month to 18 years of age) with treatment-naive, CD20-positive diffuse large B-cell lymphoma, Burkitt lymphoma, Burkitt-like lymphoma, or mature B-cell acute leukemia (B-AL) (FDA.gov).
Vincristine Sulfate	Oncovin	22-Oxovincaleukoblastine\|vincristine		Oncovin (vincristine) binds microtubules and prevents mitotic spindle formation, resulting in cell-cycle arrest (NCI Drug Dictionary).

Showing 1 to 12 of 12 entries

Filter rows:

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Filter rows:

Showing 0 to 0 of 0 entries

Showing 0 to 0 of 0 entries

Filter rows:

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Filter rows:

Showing 1 to 1 of 1 entries

Clinical Trial	Phase	Therapies	Title	Recruitment Status	Covered Countries	Other Countries
NCT01085617	Phase III	Palifermin Cyclophosphamide + Cytarabine + Daunorubicin + Etoposide + Fludarabine + Imatinib + Melphalan + Mercaptopurine + Methotrexate + Pegaspargase + Vincristine Sulfate Cyclophosphamide + Cytarabine + Daunorubicin + Etoposide + Fludarabine + Melphalan + Mercaptopurine + Methotrexate + Pegaspargase + Vincristine Sulfate Cyclophosphamide + Cytarabine + Daunorubicin + Etoposide + Fludarabine + Imatinib + Melphalan + Mercaptopurine + Methotrexate + Pegaspargase + Rituximab + Vincristine Sulfate Cyclophosphamide + Cytarabine + Daunorubicin + Etoposide + Fludarabine + Melphalan + Mercaptopurine + Methotrexate + Nelarabine + Pegaspargase + Vincristine Sulfate	Standard Chemotherapy With or Without Nelarabine or Rituximab in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (UKALL14)	Completed		0

Showing 1 to 1 of 1 entries

Filter rows:

Additional content available in CKB BOOST